Biofrontera (BFRI)

• Market cap: $6.23M
• 1 day: 1.38%
• 5 days: 11.69%
• 1 month: -8.32%
• 3 months: -29.89%
• 6 months: -37.83%
• Year to date: -39.54%
• 1 year: -33.43%
• 5 years: -99.25%
• 10 years: -99.25%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.

Employees: 93

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

6.66% less ownership

Funds ownership: 23.35% [Q4 2024] → 16.69% (-6.66%) [Q1 2025]

14% less funds holding

Funds holding: 14 [Q4 2024] → 12 (-2) [Q1 2025]

40% less capital invested

Capital invested by funds: $1.97M [Q4 2024] → $1.18M (-$788K) [Q1 2025]

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

40% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 5

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $2.75 317% upside
• Avg. target: $2.75 317% upside
• High target: $2.75 317% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Benchmark Bruce Jackson

317% upside $2.75

Buy Maintained

19 May 2025